The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis

Vaccine. 2002 Dec 13;21(3-4):174-80. doi: 10.1016/s0264-410x(02)00458-9.

Abstract

To determine if BCG was required in booster injections for autoclaved Leishmania major (ALM) vaccine, 75 volunteers with no response to leishmanin were injected double-blind and randomly with either ALM+BCG or BCG alone for the first injection and boosted either with ALM+BCG, ALM or BCG alone for the second and third. Addition of BCG to the boosters significantly increased the frequency and the magnitude of leishmanin skin tests (LSTs); however, there was no difference in proliferative and IFN-gamma responses (a month and a year later). Three injections of BCG produced no observable adverse reaction; hence BCG could be used in booster injections to increase the protective potential of this candidate vaccine.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • BCG Vaccine / immunology*
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Humans
  • Interferon-gamma / biosynthesis
  • Leishmania major / immunology*
  • Leishmaniasis / prevention & control*
  • Leishmaniasis Vaccines
  • Male
  • Middle Aged
  • Protozoan Vaccines / administration & dosage*
  • Protozoan Vaccines / immunology
  • Vaccination
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / adverse effects

Substances

  • BCG Vaccine
  • Leishmaniasis Vaccines
  • Protozoan Vaccines
  • Vaccines, Inactivated
  • autoclaved Leishmania major vaccine
  • Interferon-gamma